Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1991-9-16
|
pubmed:abstractText |
The role of physiologically secreted human IFN-gamma in T lymphocyte and NK cell activation has been probed with a panel of mouse mAb directed against various epitopes of the human IFN-gamma molecule, or human IFN-gamma R. Addition to the culture medium of those mAb that neutralize the antiviral activity of IFN-gamma or interact with its receptor inhibited proliferative and cytotoxic responses elicited in PBL by HLA alloantigens, anti-CD3 mAb, and IL-2, but not the proliferative response to PHA. The IFN-gamma blockade also inhibited IFN-gamma, IL-2, and TNF-alpha release during MLC. Kinetic experiments showed that reduction of proliferative and cytotoxic responses to HLA alloantigens is maximal when IFN-gamma is blocked within the first 48 h. Exogenous rIFN-gamma restored the proliferative response only when added at the beginning. Moreover, when IFN-gamma was blocked, T lymphocytes recovered from 6-day MLC displayed a profound decrease in their expression of p55 and p75 chains of the IL-2R, as well as in the number of high-affinity IL-2 binding sites. These findings strongly suggest that IFN-gamma is required in the early phases of induction of the oligo- and polyclonal proliferative and cytotoxic responses of lymphocytes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Isoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
147
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1445-52
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:1831225-Antibodies, Monoclonal,
pubmed-meshheading:1831225-Antigens, CD3,
pubmed-meshheading:1831225-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1831225-Cytotoxicity, Immunologic,
pubmed-meshheading:1831225-Humans,
pubmed-meshheading:1831225-Interferon-gamma,
pubmed-meshheading:1831225-Interleukin-2,
pubmed-meshheading:1831225-Isoantigens,
pubmed-meshheading:1831225-Killer Cells, Natural,
pubmed-meshheading:1831225-Lymphocyte Activation,
pubmed-meshheading:1831225-Receptors, Antigen, T-Cell,
pubmed-meshheading:1831225-Receptors, Interleukin-2,
pubmed-meshheading:1831225-T-Lymphocytes
|
pubmed:year |
1991
|
pubmed:articleTitle |
Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation.
|
pubmed:affiliation |
Institute of Microbiology, University of Turin, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|